NEWS

2021.04.15

Craif Inc. Announces Residency at JLABS @ Shanghai To Further Accelerate the Development of an Innovative Exosome Biomarker Discovery Platform

April, 2021 — Craif Inc. (formerly Icaria Inc.) (Headquarter: Bunkyo-ku, Tokyo, President & CEO: Ryuichi Onose, “Craif”) is pleased to announce that it has become a resident of Johnson & Johnson Innovation – JLABS @ Shanghai (‘JLABS’), which it considers as an important step toward further accelerating the development of an innovative exosome biomarker discovery platform, by getting access to JLABS’ global network and resources.

JLABS is a premier life science incubator program and a global network of open innovation ecosystems, which aims to enable and empower innovators to create and accelerate the delivery of potential life-enhancing health and wellness solutions to patients around the world.

Craif, a Nagoya University-originated start-up, is developing its exosome biomarker discovery platform by capturing exosomes comprehensively from urine samples with microfabrication technology. Also, by leveraging AI analytics, the platform aims to enable early detection of cancer, as well as, selecting tailored treatment for each patient from a single drop of urine.

Craif’s core technology is a unique zinc oxide nanowire-based exosome extraction device.
Containing various biomolecules including proteins and nucleic acids, exosome is attracting worldwide attention for its potential as biomarkers for various diseases.
Craif’s device can not only efficiently extract exosomes, but also detect over 1,300 types of miRNA, which is deeply related to the development and progression of diseases. Combining AI with this leading-edge technology will hopefully enable us to succeed in detecting cancer with a high degree of accuracy.
As we continue to develop our technology, we aim to further increase the accuracy of our cancer detection method to facilitate early diagnosis and the selection of appropriate treatment for individual patients using just a single drop of urine.
We will continue to strive to ultimately realize a future where no one will have to lose their battle with cancer.

CEO Ryuichi Onose